🚀 VC round data is live in beta, check it out!
Whitehawk Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Whitehawk Therapeutics and similar public comparables like Easywell Biomedicals, Scancell, Unicycive, Tetratherix and more.
Whitehawk Therapeutics Overview
About Whitehawk Therapeutics
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Founded
2007
HQ
Employees
40
Website
Sectors
Financials (LTM)
EV
$21M
Whitehawk Therapeutics Financials
Whitehawk Therapeutics reported last 12-month revenue of $5M.
In the same LTM period, Whitehawk Therapeutics generated $5M in gross profit and had net loss of ($41M).
Revenue (LTM)
Whitehawk Therapeutics P&L
In the most recent fiscal year, Whitehawk Therapeutics reported revenue of $7M and EBITDA of ($21M).
Whitehawk Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $7M | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | $6M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (287%) | XXX | XXX | XXX |
| EBIT Margin | (2129%) | XXX | (1601%) | XXX | XXX | XXX |
| Net Profit | ($41M) | XXX | ($21M) | XXX | XXX | XXX |
| Net Margin | (792%) | XXX | (288%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Whitehawk Therapeutics Stock Performance
Whitehawk Therapeutics has current market cap of $167M, and enterprise value of $21M.
Market Cap Evolution
Whitehawk Therapeutics' stock price is $3.54.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21M | $167M | 4.4% | XXX | XXX | XXX | $-0.44 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWhitehawk Therapeutics Valuation Multiples
Whitehawk Therapeutics trades at 4.1x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Whitehawk Therapeutics Financial Valuation Multiples
As of April 11, 2026, Whitehawk Therapeutics has market cap of $167M and EV of $21M.
Equity research analysts estimate Whitehawk Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Whitehawk Therapeutics has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $167M | XXX | $167M | XXX | XXX | XXX |
| EV (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | 3.3x | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (8.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Whitehawk Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Whitehawk Therapeutics Margins & Growth Rates
Whitehawk Therapeutics' revenue in the last 12 month declined by (100%).
Whitehawk Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $3.0M for the same period.
Whitehawk Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (287%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (68%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 548% | XXX | 417% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1697% | XXX | 1273% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1690% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Whitehawk Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Easywell Biomedicals | XXX | XXX | XXX | XXX | XXX | XXX |
| Scancell | XXX | XXX | XXX | XXX | XXX | XXX |
| Unicycive | XXX | XXX | XXX | XXX | XXX | XXX |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Artiva Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Whitehawk Therapeutics M&A Activity
Whitehawk Therapeutics acquired XXX companies to date.
Last acquisition by Whitehawk Therapeutics was on XXXXXXXX, XXXXX. Whitehawk Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Whitehawk Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWhitehawk Therapeutics Investment Activity
Whitehawk Therapeutics invested in XXX companies to date.
Whitehawk Therapeutics made its latest investment on XXXXXXXX, XXXXX. Whitehawk Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Whitehawk Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Whitehawk Therapeutics
| When was Whitehawk Therapeutics founded? | Whitehawk Therapeutics was founded in 2007. |
| Where is Whitehawk Therapeutics headquartered? | Whitehawk Therapeutics is headquartered in United States. |
| How many employees does Whitehawk Therapeutics have? | As of today, Whitehawk Therapeutics has over 40 employees. |
| Who is the CEO of Whitehawk Therapeutics? | Whitehawk Therapeutics' CEO is David James Lennon. |
| Is Whitehawk Therapeutics publicly listed? | Yes, Whitehawk Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Whitehawk Therapeutics? | Whitehawk Therapeutics trades under WHWK ticker. |
| When did Whitehawk Therapeutics go public? | Whitehawk Therapeutics went public in 2021. |
| Who are competitors of Whitehawk Therapeutics? | Whitehawk Therapeutics main competitors are Easywell Biomedicals, Scancell, Unicycive, Tetratherix. |
| What is the current market cap of Whitehawk Therapeutics? | Whitehawk Therapeutics' current market cap is $167M. |
| What is the current revenue of Whitehawk Therapeutics? | Whitehawk Therapeutics' last 12 months revenue is $5M. |
| What is the current revenue growth of Whitehawk Therapeutics? | Whitehawk Therapeutics revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Whitehawk Therapeutics? | Current revenue multiple of Whitehawk Therapeutics is 4.1x. |
| Is Whitehawk Therapeutics profitable? | No, Whitehawk Therapeutics is not profitable. |
| What is the current net income of Whitehawk Therapeutics? | Whitehawk Therapeutics' last 12 months net income is ($41M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.